drug
Cyclobenzaprine Hydrochloride Teva
Marketedupdated 3mo agoby Pliva Inc (Inactive)
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- drugcyclobenzaprine hydrochloride4 co-mentions · 1 sources
- drugcyclobenzaprine hydrochloride ER4 co-mentions · 1 sources
- drugMR-107A022 co-mentions · 1 sources
- drugmeloxicam SR2 co-mentions · 1 sources
- drugmeloxicam2 co-mentions · 1 sources
- companyUnichem Pharmaceuticals (USA) Inc2 co-mentions · 1 sources
- companyUnichem Laboratories Ltd2 co-mentions · 1 sources
- tagRecall2 co-mentions · 1 sources
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 5 approved and 1 investigational indication.
all catalysts(0)
nothing on the calendar yet
Trials studying Cyclobenzaprine Hydrochloride Teva
Patent cliff
source: FDA Orange Bookfirst barrier falls
Aug 15, 2028
~2.0 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (4)
- Mar 14, 2034formulationUS 10117936
- Mar 14, 2034formulationUS 10864175
- Mar 14, 2034formulationUS 9636408
- Mar 14, 2034formulationUS 9956188
FDA exclusivities (1)
- Aug 15, 2028NPNP2.0y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 10m ago
Found something off?
comments(0)
5-min edit window · permanent after that